Created On: 2020-07-15
Record Count: 15
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28542
Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.
IPSCIO Record ID: 27064
Patents means patent application serial number 09/168910 entitled Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects.
IPSCIO Record ID: 5541
Cochleate delivery vehicles wrap-up or encapsulate the drug, rather than chemically bond with the included drug. A few of the US patents include: 1) Liposome Methods and Composition 4,663,161 2) Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles 4,871,488 Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same 3. Stabilizing And Delivery Means of Biological Molecules 5,643,574. Exhibit has excellent description of technology. The exhibit does not explain, but the original licensor is the University of Medicine and Dentistry of New Jersey who granted an exclusive worldwide license to develop the cochleate technology and in some cases co-owns the patents with the corporation.
IPSCIO Record ID: 256328
IPSCIO Record ID: 280951
BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.
IPSCIO Record ID: 29101
IPSCIO Record ID: 203340
Products means any product in finished pharmaceutical form for use and sale in the Field containing the Compounds formulated with and incorporating the Patents and Know-How and covered by a Valid Claim.
It is Licensee's intention to use Licensor's licensed, Bioral(TM) nanocochleate drug delivery technology to provide for oral delivery of pharmaceutical products incorporating these compounds.
IPSCIO Record ID: 7755
The term PSMA shall mean all compositions and uses of, collectively: molecules that elicit an immune response specific for prostate specific membrane antigen.
The term TranzFect shall mean any polyoxypropylene/polyoxyethylene copolymer compound or compositions or preparations of such compounds claimed in or covered by CytRx Poloxamer Intellectual Property that may be added to Substance to enhance performance of such Substance relative to use of the Substance without Tranzfect.
US PATENT 5,554,372 Methods and vaccines comprising surface-active copolymers
US PATENT 6,086,899 Ethylene oxide-propylene oxide copolymer
US PATENT 5,824,322 Compositions and methods for growth promotion
Licensee will enter research and development activities related to the use of Transfect in the Field, to develop and commercialize a Licensed Product on a commercially reasonable basis.
IPSCIO Record ID: 7076
Antifungal Products shall mean any and all products covered by the patent rights licensed to Licensee by MAYO.
Technology refers to encochleated formulation of amphotericin B for topical treatments for CRS and asthma.
Appln No./Patent No.
BSZ-005: Liposome Methods and Composition US 4,663,161
BSZ-005DV: Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles
BSZ-006: Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same US 5,643,574
BSZ-006CP: Stabilizing Delivery Means of Biological MoleculesIntâ€™I (PC) US94/10913
IPSCIO Record ID: 227255
Licensed Product(s) means any and all products which either fall within the scope of one or more Valid Claims of the Licensed Patent Technology, or are produced by the practice of, or are made for use in, a method that is within the scope of one or more Valid Claims of the Licensed Patent Technology, in the country of manufacture or sale by Licensee or its Affiliate(s).
Licensed rights for transcutaneous vaccine system.
IPSCIO Record ID: 28637
IPSCIO Record ID: 263928
IPSCIO Record ID: 249713
â€¢ Any and all ANTIGENS expressed in Prostate Cancer
â€¢ Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
â€¢ Any and all Antigens expressed in Lung Cancer
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
IPSCIO Record ID: 4396
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
Human Telomerase Reverse Transcriptase Polypeptides
Field of Use means use of telomerase as an antigen in an immunotherapeutic product for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.
IPSCIO Record ID: 28678
The University is the owner of certain Patent Rights (as later defined in this Agreement) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed: June 7, 1995).
Patent Rights means all of the following UA intellectual property:
(a) the US Patent application No. 08/480,499 A Method for Eliciting a Thl Specific Immune Response (filed: June 7, 1995);
(b) the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), a continuation-in-part of 1.6 (a) and later issued as US Patent No. 6,168,804 (issued: January 2, 2001);
(c) the US Patent application No. 09/668,825 A Method for Eliciting a Thl Specific Immune Response, a divisional application of 1.6 (b) (filed: September 22, 2000);
(d) any US divisional patent applications covering the invention disclosed in the patent application 1.6 (b) above and the resulting patents;
(e) any US continuation-in-part application, and the resulting patents, which are directed to the invention disclosed in the patent applications described in sections 1.6 (b), (c) and (d) above;
(f) any Canadian and foreign patent applications, and the resulting patents, which are based on the invention disclosed in the patent applications described in sections 1.6(e) above; and
(g) any reissues, extensions and divisions of Canadian and foreign patents described in sections 1.6 (b), (c), (d), (e) and (f) above.